Yamada Hidetoshi, Li Yanze C, Nishikawa Mitsuo, Oshimura Mitsuo, Inoue Toshiaki
Division of Human Genome Science, Department of Molecular and Cellular Biology, Faculty of Medicine, Tottori University, 86, Nishi-cho, Yonago, 683-8503, Japan.
Division of Molecular Genetics and Biofunction, Department of Biomedical Science, Graduate School of Medicine, Tottori University, 86, Nishi-cho, Yonago, 683-8503, Japan.
J Hum Genet. 2008;53(5):447-453. doi: 10.1007/s10038-008-0268-0. Epub 2008 Mar 6.
Gene therapy using cDNA driven by an exogenous promoter is not suited for genetic disorders that require intrinsic expression of a transgene, such as hyperimmunoglobulin (Ig)M syndrome (HIGM), which is caused by mutations in the CD40L gene. The human artificial chromosome (HAC) vector has the potential to solve this problem, because it can be used to transfer large genomic fragments containing their own regulatory elements. In this study, we examined whether introduction of a genomic fragment of CD40L via the HAC vector permits intrinsic expression of the transgene and has an effect on immunoglobulin secretion. We constructed an HAC vector carrying the mouse CD40L genomic fragment (mCD40L-HAC) in Chinese hamster ovary (CHO) cells and transferred the mCD40L-HAC vector into a human CD4-positive active T-cell line (Jurkat) and a human myeloid cell line (U937) via microcell-mediated chromosome transfer (MMCT). The mCD40L-HAC vector permits mCD40L expression in human active T cells but not in human myeloid cells. The mCD40L-HAC also functions to stimulate mouse B cells derived from CD40L(-/-) mice, inducing secretion of IgG. This study may be an initial step toward the therapeutic application of HAC vectors for intrinsic expression of genes, a potential new direction for genome-based gene therapy.
使用由外源启动子驱动的互补DNA(cDNA)进行基因治疗并不适用于需要转基因固有表达的遗传性疾病,比如高免疫球蛋白(Ig)M综合征(HIGM),它是由CD40L基因的突变引起的。人类人工染色体(HAC)载体有潜力解决这个问题,因为它可用于转移包含自身调控元件的大片段基因组。在本研究中,我们检测了通过HAC载体导入CD40L基因组片段是否能使转基因固有表达并对免疫球蛋白分泌产生影响。我们在中国仓鼠卵巢(CHO)细胞中构建了携带小鼠CD40L基因组片段的HAC载体(mCD40L-HAC),并通过微细胞介导的染色体转移(MMCT)将mCD40L-HAC载体转入人CD4阳性活性T细胞系(Jurkat)和人髓细胞系(U937)。mCD40L-HAC载体能使人活性T细胞表达mCD40L,但不能使人髓细胞表达。mCD40L-HAC还能刺激源自CD40L(-/-)小鼠的小鼠B细胞,诱导IgG分泌。本研究可能是迈向HAC载体用于基因固有表达的治疗应用的第一步,这是基于基因组的基因治疗的一个潜在新方向。